Mitral valve annuloplasty double by the year 2030. Every year, 300,000 people worldwide undergo open heart surgery for mitral valve repair, 44,000 people in the US alone. Since it was initially established 40 years ago by Professor Alain Carpentier, mitral valve annuloplasty has been continuously improved and is considered the gold standard for the treatment of most etiologies of mitral valve dysfunction today. The goal of mitral valve annuloplasty is to regain mitral valve competence by restoring the physiological form and function of the normal mitral valve apparatus. Under normal conditions the mitral valve undergoes significant dynamic changes in shape and size throughout
Mitral valve annuloplasty the native annulus and some of its natural dynamics. The goal of semi-rigid rings is to maintain coaptation and valve integrity during systole, while allowing for good hemodynamics during diastole. Rigid rings are designed to provide rigid support in large dilation and under high-pressure. Annuloplasty devices usually come in different sizes. The surgeon can estimate the dimensions of the patient’s mitral valve and decide on an appropriate ring size. Depending on the disease etiology, different approaches are taken. Surgeons can decide to "undersize" the device, "truesize" the device, or "oversize" it. Annuloplasty devices are classified by the U.S. Food and